Business Description
Coegin Pharma
ISIN : SE0020357754
Share Class Description:
NGM:COEGIN: Ordinary SharesTotal Employee Number:
3Compare
Compare
Traded in other countries / regions
7Z6.GermanyCOEGIN.Sweden IPO Date
2018-02-21Description
Coegin Pharma AB is a Swedish biotechnology company with projects in hair growth, skin pigmentation, heart attacks, and leukemia. Its project portfolio builds on three distinct, patented technology platforms: the FOL peptide technology, the pigmentation peptide technology, and the cPLA2 alpha technology. The company's project portfolio consists of both cosmetic dermatology and drug development projects. Currently, it is focused on the cosmetic dermatology projects, which include the NPP-4 project for skin pigmentation and the Follicopeptide project for hair growth. In addition, the company's project portfolio also includes three drug development projects: FOL026, for the treatment of myocardial infarction (heart attack); AVX420 for the treatment of leukemia; and AVX001.
Financial Strength
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | No Debt | |||||
Equity-to-Asset | 0.84 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 20.81 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -152 | |||||
3-Year EPS without NRI Growth Rate | -146.6 | |||||
3-Year FCF Growth Rate | -130.2 | |||||
3-Year Book Growth Rate | 81.7 |
Momentum Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 38.39 | |||||
9-Day RSI | 42.36 | |||||
14-Day RSI | 44.24 | |||||
3-1 Month Momentum % | -1.6 | |||||
6-1 Month Momentum % | -13.75 | |||||
12-1 Month Momentum % | 9.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 5.13 | |||||
Quick Ratio | 5.13 | |||||
Cash Ratio | 4.13 | |||||
Days Sales Outstanding | 75.15 | |||||
Days Payable | 210.18 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 67 | |||||
Shareholder Yield % | -7.65 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -167.65 | |||||
Operating Margin % | -5279.41 | |||||
Net Margin % | -5311.77 | |||||
EBITDA Margin % | -4470.59 | |||||
FCF Margin % | -4870.35 | |||||
OCF Margin % | -4870.35 | |||||
ROE % | -155.07 | |||||
ROA % | -121.55 | |||||
ROIC % | -278.9 | |||||
3-Year ROIIC % | -83.96 | |||||
ROC (Joel Greenblatt) % | -14475.81 | |||||
ROCE % | -154.16 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 275.72 | |||||
PB Ratio | 7.07 | |||||
Price-to-Tangible-Book | 9.11 | |||||
EV-to-EBIT | -4.48 | |||||
EV-to-EBITDA | -5.28 | |||||
EV-to-Revenue | 236.14 | |||||
EV-to-FCF | -4.62 | |||||
| Price-to-Net-Current-Asset-Value | 9.11 | |||||
| Price-to-Net-Cash | 14.04 | |||||
Earnings Yield (Greenblatt) % | -22.34 | |||||
FCF Yield % | -18.7 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coegin Pharma Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | 0.371 | ||
| EPS (TTM) (kr) | -0.79 | ||
| Beta | 0.5094 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 101.74 | ||
| 14-Day RSI | 44.24 | ||
| 14-Day ATR (kr) | 0.332834 | ||
| 20-Day SMA (kr) | 3.504 | ||
| 12-1 Month Momentum % | 9.14 | ||
| 52-Week Range (kr) | 2.82 - 9.98 | ||
| Shares Outstanding (Mil) | 28.59 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coegin Pharma Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coegin Pharma Stock Events
| Event | Date | Price (kr) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-20 | In 133 days | ||
| Second quarter earnings results for 2026 | 2026-08-21 | In 42 days | ||
| General meeting for 2026 | 2026-05-21 10:00 | 3.66 (-8.27%) | ||
| First quarter earnings results for 2026 | 2026-04-28 | 4.17 (+1.21%) | ||
| Annual report for 2025 | 2026-03-31 | 3.74 (-2.09%) | ||
| Fourth quarter earnings results for 2025 | 2026-02-26 | 4.24 (+4.18%) | ||
| Third quarter earnings results for 2025 | 2025-11-20 | 5.60 (-3.45%) | ||
| Second quarter earnings results for 2025 | 2025-08-21 | 3.11 (+3.67%) | ||
| General meeting for 2025 | 2025-05-22 11:00 | 3.50 (-3.85%) | ||
| First quarter earnings results for 2025 | 2025-05-22 | 3.50 (-3.85%) |
Show
Entries
Coegin Pharma Frequently Asked Questions
What is Coegin Pharma(NGM:COEGIN)'s stock price today?
The current price of NGM:COEGIN is kr3.37. The 52 week high of NGM:COEGIN is kr9.98 and 52 week low is kr2.82.
When is next earnings date of Coegin Pharma(NGM:COEGIN)?
The next earnings date of Coegin Pharma(NGM:COEGIN) is 2026-08-21 Est..
Does Coegin Pharma(NGM:COEGIN) pay dividends? If so, how much?
Coegin Pharma(NGM:COEGIN) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Coegin Pharma
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers